Safety and pharmacokinetics of EP-104IAR (sustained-release fluticasone propionate) in knee osteoarthritis: A randomized, double-blind, placebo-controlled phase 1 trial

OBJECTIVE: EP-104IAR is a novel, sustained-release, intra-articular (IA) formulation of the corticosteroid fluticasone propionate (FP), in development for the treatment of osteoarthritis (OA) pain. This study evaluated the safety, pharmacokinetics (PK) and efficacy of a single dose of EP-104IAR in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Malone, Amanda, Price, James, Price, Nicola, Peck, Vik, Getgood, Alan, Petrella, Robert, Helliwell, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718298/
https://www.ncbi.nlm.nih.gov/pubmed/36474755
http://dx.doi.org/10.1016/j.ocarto.2021.100213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718298/
https://www.ncbi.nlm.nih.gov/pubmed/36474755
http://dx.doi.org/10.1016/j.ocarto.2021.100213

Ejemplares similares